Quarterly report pursuant to Section 13 or 15(d)

Basis of Presentation (Details)

v3.22.0.1
Basis of Presentation (Details) - USD ($)
3 Months Ended 6 Months Ended
Jan. 31, 2022
Jan. 31, 2021
Jan. 31, 2022
Jan. 31, 2021
Basis of Presentation (Details) [Line Items]        
Revenue (in Dollars) $ 34,046,000 $ 31,466,000 $ 60,565,000 $ 60,121,000
Accounts receivable net     32.00%  
Fair value investments (in Dollars)     $ 29,480,000  
Cost of marketable securities (in Dollars)     30,116,000  
Unrealized losses marketable securities (in Dollars) 357,000   $ 553,000  
Life Sciences segment’s [Member]        
Basis of Presentation (Details) [Line Items]        
Concentration risk, percentage     16.00%  
Clinical Services [Member]        
Basis of Presentation (Details) [Line Items]        
Concentration risk, percentage     35.00% 34.00%
Revenue (in Dollars) $ 23,674,000 $ 23,988,000 $ 43,415,000 $ 45,211,000
Clinical Services [Member] | Third-Party Payers” and “Health Maintenance Organizations [Member]        
Basis of Presentation (Details) [Line Items]        
Concentration risk, percentage 27.00%      
Clinical Services [Member] | Revenue [Member] | Third-Party Payers” and “Health Maintenance Organizations [Member]        
Basis of Presentation (Details) [Line Items]        
Concentration risk, percentage 36.00% 35.00%    
Life Sciences segment’s [Member]        
Basis of Presentation (Details) [Line Items]        
Concentration risk, percentage 27.00%      
Revenue (in Dollars) $ 2,800   $ 2,800  
Life Sciences segment’s [Member] | One Customer [Member]        
Basis of Presentation (Details) [Line Items]        
Concentration risk, percentage 16.00%   27.00%